AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15601811 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated sumatriptan (100 mg)
Number of subjects: 10
Study 15601811 — intervention group
Group type: COMPARATOR
Intervention: Nonencapsulated sumatriptan (100 mg)
Number of subjects: 10
Study 11883108 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive diagnostics and revascularization therapy
Number of subjects: 0
Study 11883108 — intervention group
Group type: EXPERIMENTAL
Intervention: Case fatality rate after 30 days
Number of subjects: 0
Study 11883108 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of myocardial infarction
Number of subjects: 0
Study 10352534 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) transdermal treatment 50 micrograms (TTS 50) continuously administered plus Medroxyprogesterone Acetate (MPA) 10 mg/die for twelve days a month (Group A)
Number of subjects: 110
Study 10352534 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Equine Estrogens (CEE) 0.625 mg/die continuously plus MPA for twelve days a month (Group B)
Number of subjects: 110
Study 10352534 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol transdermal 50 micrograms continuously plus MPA 2.5 mg/die continuously (Group C)
Number of subjects: 110
Study 10352534 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/die continuously plus MPA 2.5 mg/die continuously (Group D)
Number of subjects: 110
Study 8749695 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 60
Study 8749695 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) with total body irradiation
Number of subjects: 60
Study 1780205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 ml/kg of 95% ethanol, plus diluent
Number of subjects: 8
Study 1780205 — intervention group
Group type: COMPARATOR
Intervention: Diluent (placebo condition)
Number of subjects: 8
Study 6109938 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis B vaccine (3 doses at one-month intervals)
Number of subjects: 100
Study 6109938 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria/tetanus/polio vaccine (Control)
Number of subjects: 100
Study 6109938 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis B vaccine
Number of subjects: 100
Study 30887865 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 4 mg
Number of subjects: 45
Study 30887865 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 16 mg
Number of subjects: 45
Study 30887865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30887865 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (7.5 mg intravenously)
Number of subjects: 45
Study 30887865 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (all doses)
Number of subjects: 45
Study 27933667 — intervention group
Group type: EXPERIMENTAL
Intervention: SleepMapper
Number of subjects: 61
Study 25687484 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitatory Kinesio tape
Number of subjects: 33
Study 25687484 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory Kinesio tape
Number of subjects: 33
Study 25687484 — intervention group
Group type: COMPARATOR
Intervention: No tape (tapeless condition)
Number of subjects: 33
Study 24433837 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Assisted Reduction then Stop (EARS) intervention
Number of subjects: 99
Study 24433837 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 22779219 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gingival patch
Number of subjects: 26
Study 22779219 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 26
Study 19641261 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of online lifestyle diary with computer assistant feedback
Number of subjects: 118
Study 19641261 — intervention group
Group type: COMPARATOR
Intervention: Use of online lifestyle diary without computer assistant feedback
Number of subjects: 118
Study 17656440 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine capsules (dose = 5 mg kg(‐1)) and saline infusion ([ADR] = 0.62 nm)
Number of subjects: 8
Study 17656440 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules and saline infusion ([ADR] = 0.29 nm)
Number of subjects: 8
Study 17656440 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo capsules and ADR infusion ([ADR] = 1.19 nm)
Number of subjects: 8
Study 17656440 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine capsules (dose = 5 mg kg(‐1)) and ADR infusion ([ADR] = 0.93 nm)
Number of subjects: 8
Study 16275937 — intervention group
Group type: EXPERIMENTAL
Intervention: PCF (paclitaxel 175 mg/m2 on day 1, cisplatin 100 mg/m2 on day 2, FU 500 mg/m2 continuous infusion on days 2 through 6)
Number of subjects: 382
Study 16275937 — intervention group
Group type: COMPARATOR
Intervention: CF (cisplatin 100 mg/m2 on day 1 plus FU 1000 mg/m2 continuous infusion on days 1 through 5)
Number of subjects: 382
Study 16275937 — intervention group
Group type: EXPERIMENTAL
Intervention: PCF
Number of subjects: 382
Study 16275937 — intervention group
Group type: COMPARATOR
Intervention: CF
Number of subjects: 382
Study 12064491 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine (experimental group)
Number of subjects: 83
Study 12064491 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 83
Study 10215237 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 46
Study 10215237 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 46
Study 8536900 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (25, 50, or 100 micrograms diluted in normal saline solution)
Number of subjects: 100
Study 8536900 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 100
Study 1591117 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinned restorations
Number of subjects: 40
Study 1591117 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgambond restorations
Number of subjects: 40
Study 1591117 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia‐Ex restorations
Number of subjects: 40
Study 1591117 — intervention group
Group type: COMPARATOR
Intervention: Copal varnish (control)
Number of subjects: 40
Study 6690375 — intervention group
Group type: EXPERIMENTAL
Intervention: Picolax alone
Number of subjects: 160
Study 6690375 — intervention group
Group type: COMPARATOR
Intervention: X‐Prep alone
Number of subjects: 160
Study 6690375 — intervention group
Group type: EXPERIMENTAL
Intervention: Picolax plus lavage
Number of subjects: 160
Study 6690375 — intervention group
Group type: COMPARATOR
Intervention: X‐Prep plus lavage
Number of subjects: 160
Study 6690375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction
Number of subjects: 160
Study 6690375 — intervention group
Group type: COMPARATOR
Intervention: Mechanical lavage
Number of subjects: 160
Study 31197967 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary posterior capsulorhexis (PPCR)
Number of subjects: 97
Study 31197967 — intervention group
Group type: COMPARATOR
Intervention: No primary posterior capsulorhexis (No PPCR)
Number of subjects: 97
Study 29362206 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital mail invitation (e-Boks)
Number of subjects: 7200
Study 29362206 — intervention group
Group type: COMPARATOR
Intervention: Paper mail invitation
Number of subjects: 7200
Study 27116645 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise (GE)
Number of subjects: 24
Study 27116645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Exercise (IE)
Number of subjects: 24
Study 27116645 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care (UC)
Number of subjects: 24
Study 27116645 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 24
Study 26203643 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block plus physical therapy (PT)
Number of subjects: 41
Study 26203643 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT) alone
Number of subjects: 41
Study 23208648 — intervention group
Group type: EXPERIMENTAL
Intervention: Group couple-based intervention (n=112)
Number of subjects: 216
Study 23208648 — intervention group
Group type: COMPARATOR
Intervention: Individual couple-based intervention (n=104)
Number of subjects: 216
Study 21076241 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen Online Problem Solving (TOPS)
Number of subjects: 41
Study 21076241 — intervention group
Group type: COMPARATOR
Intervention: Internet resource comparison (control)
Number of subjects: 41
Study 18198942 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type strain of Staphylococcus aureus
Number of subjects: 16
Study 18198942 — intervention group
Group type: COMPARATOR
Intervention: ClfB knock-out mutant strain of Staphylococcus aureus
Number of subjects: 16
Study 16861591 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer risk education and prevention programs
Number of subjects: 481
Study 14551523 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa inhibitors
Number of subjects: 0
Study 14551523 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 14551523 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab therapy
Number of subjects: 0
Study 10757081 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin (ubenimex) 10, 30, 90, and 180 mg/day for 60 days after BMT
Number of subjects: 65
Study 10757081 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin (ubenimex)
Number of subjects: 65
Study 10757081 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 65
Study 9118049 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (150 U/kg 3 times per week for 3 weeks, increased to 300 U/kg and 450 U/kg for nonresponders)
Number of subjects: 36
Study 9118049 — intervention group
Group type: COMPARATOR
Intervention: Control group (no r‐HuEPO)
Number of subjects: 36
Study 8353547 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic plus laser therapy (group II)
Number of subjects: 104
Study 8353547 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy (group I)
Number of subjects: 104
Study 2887123 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 0
Study 2887123 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine maleate
Number of subjects: 0
Study 31282699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad videos (n = 71)
Number of subjects: 197
Study 31282699 — intervention group
Group type: COMPARATOR
Intervention: Neutral videos (n = 65)
Number of subjects: 197
Study 31282699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad noncriers (n = 61)
Number of subjects: 197
Study 31282699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad criers (n = 71)
Number of subjects: 197
Study 29205487 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 260
Study 29205487 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 260
Study 27038714 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1981
Study 27038714 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent (ZES-S)
Number of subjects: 1981
Study 27038714 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stent (BMS)
Number of subjects: 1981
Study 27038714 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1981
Study 27038714 — intervention group
Group type: COMPARATOR
Intervention: EES
Number of subjects: 1981
Study 27038714 — intervention group
Group type: COMPARATOR
Intervention: ZES-S
Number of subjects: 1981
Study 25318892 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity electro-acupuncture (EA)
Number of subjects: 111
Study 25318892 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity electro-acupuncture (EA)
Number of subjects: 111
Study 25318892 — intervention group
Group type: COMPARATOR
Intervention: Medicine-controlled (MC) group (5 mg mosapride citrate, 3 times/day for 4 weeks)
Number of subjects: 111
Study 22434460 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy of the hip for FAI
Number of subjects: 612
Study 20868559 — intervention group
Group type: EXPERIMENTAL
Intervention: LCAHFR combined with FP chemotherapy
Number of subjects: 2030
Study 20868559 — intervention group
Group type: COMPARATOR
Intervention: LCAHFR
Number of subjects: 2030
Study 17369784 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term dynamic exercises
Number of subjects: 0
Study 17369784 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric resistance exercises
Number of subjects: 0
Study 17369784 — intervention group
Group type: COMPARATOR
Intervention: Postural and proprioceptive exercises
Number of subjects: 0
Study 17369784 — intervention group
Group type: COMPARATOR
Intervention: Very low intensity exercises
Number of subjects: 0
Study 16083533 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% hyaluronic acid and 1% silver sulfadiazine (HA-SSD)
Number of subjects: 111
Study 16083533 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine (SSD)
Number of subjects: 111
Study 12177656 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-limited exercise test
Number of subjects: 27
Study 12177656 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise training session
Number of subjects: 27
Study 8064328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole and trimethoprim (Bactrim)
Number of subjects: 1
Study 8064328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 3399778 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 18
Study 3399778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3399778 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam and Placebo
Number of subjects: 18
Study 31978237 — intervention group
Group type: EXPERIMENTAL
Intervention: CareNavRN™ intervention (home health nurse visits once per week for 4 weeks)
Number of subjects: 40
Study 31978237 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 40
Study 31978237 — intervention group
Group type: EXPERIMENTAL
Intervention: CareNavRN™ intervention
Number of subjects: 40
Study 30445611 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein, low-density lipoprotein (LDL), total cholesterol, and triglycerides
Number of subjects: 0
Study 28294557 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (Tp)
Number of subjects: 41
Study 28294557 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 41
Study 25307976 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoid treatment
Number of subjects: 69
Study 25307976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glucocorticoid treatment)
Number of subjects: 69
Study 23506013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm receives eight SMS messages/week, one Email/week, personalized coaching calls during weeks 0, 2, 5, 8, and 11
Number of subjects: 354
Study 23506013 — intervention group
Group type: COMPARATOR
Intervention: Control arm receives four SMS text messages
Number of subjects: 354
Study 23506013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 354
Study 22783687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel chromium brackets (OS)
Number of subjects: 38
Study 19010943 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (ICARUSS model)
Number of subjects: 186
Study 19010943 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 186
Study 16960178 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+Pro+Leu
Number of subjects: 16
Study 16960178 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 16
Study 14764753 — intervention group
Group type: EXPERIMENTAL
Intervention: T enanthate, 200 mg im every 2 weeks with placebo pills daily (T-only)
Number of subjects: 70
Study 14764753 — intervention group
Group type: EXPERIMENTAL
Intervention: T enanthate, 200 mg every 2 weeks with 5 mg finasteride daily (T+F)
Number of subjects: 70
Study 14764753 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections and pills
Number of subjects: 70
Study 11321143 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden mutation presence in patients with CRVO
Number of subjects: 0
Study 11321143 — intervention group
Group type: COMPARATOR
Intervention: Factor V Leiden mutation presence in clinic control patients
Number of subjects: 0
Study 11321143 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of factor V Leiden with CRVO
Number of subjects: 0
Study 8989254 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 for 30 days (subgroup A)
Number of subjects: 68
Study 8989254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone‐acetate for 30 days (subgroup B)
Number of subjects: 68
Study 8989254 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 plus medroxyprogesterone‐acetate for 30 days (subgroup C)
Number of subjects: 68
Study 8989254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 10146972 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 150mg twice daily
Number of subjects: 238
Study 10146972 — intervention group
Group type: COMPARATOR
Intervention: cefaclor 250mg thrice daily
Number of subjects: 238
Study 10146972 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 238
Study 10146972 — intervention group
Group type: COMPARATOR
Intervention: cefaclor
Number of subjects: 238
Study 2647644 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 197
Study 2647644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 17894113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilantin (diphenyldantoin)
Number of subjects: 0
Study 17894113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31696598 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily (QD)
Number of subjects: 44
Study 31696598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29070442 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Recovery Therapy (SRT)
Number of subjects: 50
Study 29070442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 26541060 — intervention group
Group type: EXPERIMENTAL
Intervention: 875 µg (35 000 IU) cholecalciferol (vitamin D3) per week
Number of subjects: 160
Study 26541060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 160
Study 25966665 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (15 mg single oral dose)
Number of subjects: 32
Study 25966665 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 32
Study 25966665 — intervention group
Group type: EXPERIMENTAL
Intervention: M4 (major metabolite of edoxaban)
Number of subjects: 32
Study 24005274 — intervention group
Group type: EXPERIMENTAL
Intervention: Epistop‐3 three‐balloon silicone catheter
Number of subjects: 48
Study 24005274 — intervention group
Group type: COMPARATOR
Intervention: Gauze packs
Number of subjects: 48
Study 22243943 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein diet (NP, 1 g protein:2 g carbohydrate)
Number of subjects: 54
Study 22243943 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (LP, 1 g protein:4 g carbohydrate)
Number of subjects: 54
Study 22243943 — intervention group
Group type: COMPARATOR
Intervention: High protein diet (HP, 1 g protein:1 g carbohydrate)
Number of subjects: 54
Study 19710156 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (182 mg d,l‐alpha‐tocopherol)
Number of subjects: 110
Study 19710156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 17257531 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 31
Study 17257531 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft (iliac crest bone graft)
Number of subjects: 31
Study 15295748 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a 3‐dimensional computer game during a 4‐week period consisting of twelve 90‐minute sessions.
Number of subjects: 1
Study 12594876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator weaning protocol (WP)
Number of subjects: 95
Study 12594876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator weaning protocol (WP) + chlorhexidine 0.12% oral rinse administered twice daily
Number of subjects: 95
Study 9743218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fc gamma receptor II (Fc gammaRII) and Fc gamma receptor III (Fc gammaRIII) expression on monocytes stained with specific monoclonal antibodies (IV.3 and 3G8)
Number of subjects: 0
Study 9743218 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired clearance function
Number of subjects: 0
Study 7848929 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA) with 0.1% bupivacaine, 0.01% morphine sulfate
Number of subjects: 462
Study 7848929 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 462
Study 7848929 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 462
Study 3240766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg)
Number of subjects: 12
Study 3240766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 12
Study 3240766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30903118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride sealants
Number of subjects: 400
Study 30903118 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fluoride sealants
Number of subjects: 400
Study 30903118 — intervention group
Group type: COMPARATOR
Intervention: Sealant placement (both fluoride and non-fluoride)
Number of subjects: 400
Study 28477306 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 34